The information requested is not held by primary care trust area. However, the following tables set out the relevant information by national health service trust area.
Local urology multi-disciplinary teams (MDTs) non-compliant with “Manual for cancer services 2004” measure 2G-114—
“There should be an operational policy for the team whereby it is intended that all new cancer patients will be reviewed by a multi-disciplinary team”—
as reviewed in the first round of the National Cancer Peer Review 2004-07 are as follows.
Trust Team Lancashire Teaching Hospitals NHS Trust MDT—Lancashire Teaching Hospitals Wrightington, Wigan and Leigh NHS Trust MDT—Wrightington, Wigan and Leigh Aintree Hospitals NHS Trust MDT—Aintree Wirral Hospital NHS Trust MDT—Wirral James Paget Healthcare NHS Trust MDT—James Paget Ealing Hospital NHS Trust MDT—Ealing Hospital North Middlesex University Hospital NHS Trust MDT—North Middlesex University Hospital Royal Free Hampstead NHS Trust MDT—Royal Free Guy’s and St. Thomas’ NHS Trust MDT—Guys and St. Thomas Milton Keynes General Hospital NHS Trust MDT—Milton Keynes General Surrey and Sussex Healthcare NHS Trust MDT—East Surrey Hospital East Sussex Hospitals NHS Trust MDT—Eastbourne
Specialist urology MDTs non-compliant with Manual for cancer services 2004 measure 2G-114—
“There should be an operational policy for the team whereby it is intended that all new cancer patients will be reviewed by a multi-disciplinary team”—
as reviewed in the first round of the National Cancer Peer Review 2004-07 are as follows.
Trust Team University College London Hospitals NHS Trust/Royal Free Hospital NHS Trust MDT—North London Joint Cancer Centre Plymouth Hospitals NHS Trust MDT—Plymouth
The Department has made the following estimates of the number of new cases of prostate cancer.
New cases (estimate) 2011 29,625 2016 33,026 2021 36,703
(2) pursuant to the answer of 25 February 2008, Official Report, column 1214W, on prostate cancer, whether the Prostate Cancer Risk Management programme was discussed at the meeting with representatives of the Prostate Cancer Charter for Action of 7 November 2007; and if he will make a statement.
I can confirm that the revision of the Prostate Cancer Risk Management programme (PCRMP) was discussed at my meeting with representatives of the Prostate Cancer Charter for Action on 7 November 2007. Subsequently representatives of the Charter have been members of a small group convened by national health service cancer screening programmes to consult on and oversee the revision of the PCRMP materials. This revision is ongoing, and an exercise seeking the views of key stakeholders will take place on the revised materials in May 2008 prior to the relaunch of the PCRMP in June 2008.
The Department has not made any such estimates.